Article ; Online: Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.
2024 Volume 34, Issue 4, Page(s) 1324–1332
Abstract: Background: Metabolic and bariatric surgery (MBS) is the most effective treatment for obesity and improvement of obesity-associated comorbidities. However, a proportion of these patients may suffer from weight recurrence and recurrence of obesity- ... ...
| Abstract | Background: Metabolic and bariatric surgery (MBS) is the most effective treatment for obesity and improvement of obesity-associated comorbidities. However, a proportion of these patients may suffer from weight recurrence and recurrence of obesity-associated comorbidities. Method: A retrospective cohort study of patients who underwent SG between January 2008 and August 2022 and sought treatment for weight recurrence with semaglutide or tirzepetide from January 2022 onwards. Result: A total of 115 patients were included, of which 70 had SG and treated for weight recurrence with semaglutide and 45 had SG and treated with tirzepatide. The mean age of patients was 38.8 (10.4) and 80.9% of patients were female. The mean pre-treatment weight and BMI was 94.0 (23.8) kg and 35.1 (6.0) kg/m Conclusion: Short-term outcomes show that semaglutide and tirzepatide can be an effective treatment for managing weight recurrence after SG. Studies with longer follow-up are needed to determine the durability, as weight regain after discontinuation of the medication is highly likely, and the high cost of these medications can limit their use. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Humans ; Female ; Male ; Obesity, Morbid/surgery ; Retrospective Studies ; Obesity/surgery ; Treatment Outcome ; Gastrectomy/adverse effects ; Weight Loss ; Glucagon-Like Peptide-2 Receptor ; Glucagon-Like Peptides ; Gastric Inhibitory Polypeptide | |||||
| Chemical Substances | tirzepatide (OYN3CCI6QE) ; semaglutide (53AXN4NNHX) ; Glucagon-Like Peptide-2 Receptor ; Glucagon-Like Peptides (62340-29-8) ; Gastric Inhibitory Polypeptide (59392-49-3) | |||||
| Language | English | |||||
| Publishing date | 2024-03-02 | |||||
| Publishing country | United States | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 1070827-3 | |||||
| ISSN | 1708-0428 ; 0960-8923 | |||||
| ISSN (online) | 1708-0428 | |||||
| ISSN | 0960-8923 | |||||
| DOI | 10.1007/s11695-024-07137-0 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 3381: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.